Citations

Clear

3942 citation(s) found for "To, Van".

Patient‐control association study of the Leucine‐Rich repeat kinase 2 (LRRK2) gene in South African Parkinson's disease patients
Bardien, Soraya , Blanckenberg, Janine, Merwe, Lize van der , Farrer, Matthew J. , Ross, Owen A. , Ross, Owen A , Bardien, Soraya

Mayo Clinic

Movement Disorders | September 6, 2013 | Volume: 28 | Issue: 14 | Pages: 2039-2040

10.1002/mds.25637 | PMID 24014121 Get It

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
Xu‐Monette, Zijun Y. , Møller, Michael , Tzankov, Alexandar , Montes‐Moreno, Santiago , Hu, Wenwei , Manyam, Ganiraju C. , Kristensen, Louise , Fan, Lei , Visco, Carlo , Dybkær, Karen , Chiu, April , Tam, Wayne , Zu, Youli , Richards, Kristy L. , Choi, William W.L., Krieken, J. Han van , Huang, Qin , Huh, Jooryung , Ferreri, Andrés J.M. , Zhao, Xiaoying , Bueso‐Ramos, Carlos E. , Wang, Sa A. , Winter, Jane N. , Piris, Miguel Á. , Medeiros, L. Jeffrey , Young, Ken H. , Bhagat, Govind , Hsi, Eric D. , Ai, Weiyun Z. , Ponzoni, Maurilio , Wu, Lin , Go, Ronald S. , Li, Yong , Møller, Michael Boe , Winter, Jane N , Tzankov, Alexandar , Dybkaer, Karen , van Krieken, J Han , Young, Ken H , Piris, Miguel , Medeiros, L Jeffrey , Zu, Youli , Montes-Moreno, Santiago , Xu-Monette, Zijun Y

Mayo Clinic

Blood | August 28, 2013 | Volume: 122 | Issue: 15 | Pages: 2630-2640

10.1182/blood-2012-12-473702 | PMID 23982177 Get It

Key PointsPhenotypic and genotypic profiling of MDM2 in DLBCL. MDM2 as a negative regulator of p53 tumor suppressor function.
Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis
Greipp, Patricia T. , Smoley, Stephanie A., Viswanatha, David S., Frederick, Lori S., Rabe, Kari G. , Sharma, Ruchi , Dyke, Daniel L. Van , Tschumper, Renee C. , Slager, Susan L. , Shanafelt, Tait D. , Zent, Clive S. , Chaffee, Kari G. , Greipp, Patricia T

Mayo Clinic

British Journal of Haematology | August 27, 2013 | Volume: 163 | Issue: 3 | Pages: 326-333

10.1111/bjh.12534 | PMID 24032430 Get It

SummaryDetection of a 17p13.1 deletion (loss of TP53) or 11q22.3 deletion (loss of ATM), by fluorescence in situ hybridization (FISH), in chronic lymphocytic leukaemia (CLL) patients is associated with a poorer prognosis. Because TP53 and ATM are integral to the TP53 pathway, we hypothesized that 17p13.1‐ (17p‐) and 11q22.3‐ (11q‐) occurring in the same cell (clonal 17p‐/11q‐) would confer a worse prognosis than either 17p‐ or 11q‐. We studied 2184 CLL patients with FISH (1995–2012) for the first occurrence of 17p‐, 11q‐, or clonal 17p‐/11q‐. Twenty (1%) patients had clonal 17p–/11q‐, 158 (7%) had 17p‐ (including 4 with 17p‐ and 11q‐ in separate clones), 247 (11%) had 11q‐, and 1759 (81%) had neither 17p‐ nor 11q‐. Eleven of 15 (73%) tested patients with clonal 17p‐/11q‐ had dysfunctional TP53 mutations. Overall survival for clonal 17p‐/11q‐ was significantly shorter (1·9 years) than 17p‐ (3·1 years, P = 0·04), 11q‐ (4·8 years, P ≤ 0·0001), or neither 17p‐ nor 11q‐ (9·3 years, P ≤ 0·0001). Clonal 17p‐/11q‐ thus conferred significantly worse prognosis, suggesting that loss of at least one copy of both TP53 and ATM causes more aggressive disease. Use of an ATM/TP53 combination FISH probe set could identify these very‐high risk patients.
Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database
Shi, Qian , André, Thierry , Yothers, Greg , Bot, Brian M. , Haller, Daniel G. , Twelves, Chris , Benedetti, Jacqueline, Grothey, Axel , Hamilton, Stanley R. , Cutsem, Eric Van , O’Connell, Michael J. , Sargent, Daniel J. , André, Thierry , Shi, Qian , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | August 27, 2013 | Volume: 31 | Issue: 29 | Pages: 3656-3663

10.1200/jco.2013.49.4344 | PMID 23980089 Get It

Purpose With improved patient care, better diagnosis, and more treatment options after tumor recurrence, outcomes after fluorouracil (FU) -based treatment are expected to have improved over time in early-stage colon cancer. Data from 18,449 patients enrolled onto 21 phase III trials conducted from 1978 to 2002 were evaluated for potential differences in time to recurrence (TTR), time from recurrence to death (TRD), and overall survival (OS) with regard to FU-based adjuvant regimens. Methods Trials were predefined as old versus newer era using initial accrual before or after 1995. Outcomes were compared between patients enrolled onto old- or newer-era trials, stratified by stage. Results Within the first 3 years, recurrence rates were lower in newer- versus old-era trials for patients with stage II disease, with no differences among those with stage III disease. Both TRD and OS were significantly longer in newer-era trials overall and within each stage. The lymph node (LN) ratio (ie, number of positive nodes divided by total nodes harvested) in those with stage III disease declined over time. TTR improved slightly, with larger number of LNs examined in both stages. Conclusion Improved TRD in newer trials supports the premise that more aggressive intervention (oxaliplatin- and irinotecan-based chemotherapy and/or surgery for recurrent disease) improves OS for patients previously treated in the adjuvant setting. Lower recurrence rates with identical treatments in those with stage II disease enrolled onto newer-era trials reflect stage migration over time, calling into question historical data related to the benefit of FU-based adjuvant therapy in such patients.
Systems Approaches Evolve Clinical Pharmacology
Waldman, Scott A. , Graaf, PH van der, Terzic, André , Waldman, Scott A

Mayo Clinic

CPT: Pharmacometrics & Systems Pharmacology | August 21, 2013 | Volume: 2 | Issue: 8 | Pages: 1-2

10.1038/psp.2013.48 | PMID 23965784 Get It

CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e68; doi:10.1038/psp.2013.48; advance online publication 21 August 2013
Search for genetic modifiers of IRF6 and genotype–phenotype correlations in Van der Woude and popliteal pterygium syndromes
Leslie, Elizabeth J. , Mancuso, Jennifer L., Schutte, Brian C. , Cooper, Margaret E., Durda, Kate, L’Heureux, Jamie, Zucchero, Theresa M., Marazita, Mary L. , Murray, Jeffrey C.

Mayo Clinic

American Journal of Medical Genetics Part A | August 15, 2013 | Volume: 161 | Issue: 10 | Pages: 2535-2544

10.1002/ajmg.a.36133 | PMID 23949966 Get It

ABSTRACTVan der Woude syndrome is the most common form of syndromic orofacial clefting, accounting for 1–2% of all patients with cleft lip and/or cleft palate. Van der Woude and popliteal pterygium syndromes are caused by mutations in IRF6, but phenotypic variability within and among families with either syndrome suggests that other genetic factors contribute to the phenotypes. The aim of this study was to identify common variants acting as genetic modifiers of IRF6 as well as genotype–phenotype correlations based on mutation type and location. We identified an association between mutations in the DNA‐binding domain of IRF6 and limb defects (including pterygia). Although we did not detect formally significant associations with the genes tested, borderline associations suggest several genes that could modify the VWS phenotype, including FOXE1, TGFB3, and TFAP2A. Some of these genes are hypothesized to be part of the IRF6 gene regulatory network and may suggest additional genes for future study when larger sample sizes are also available. We also show that families with the Van de Woude phenotype but in whom no mutations have been identified have a lower frequency of cleft lip, suggesting there may be locus and/or mutation class differences in Van de Woude syndrome. © 2013 Wiley Periodicals, Inc.
FGFR1 Signaling Stimulates Proliferation of Human Mesenchymal Stem Cells by Inhibiting the Cyclin-Dependent Kinase Inhibitors p21Waf1 and p27Kip1
Dombrowski, Christian, Helledie, Torben, Grünert, Martin, Canning, Claire Ann, Jones, C. Michael , Hui, James Hoi Po , Nurcombe, Victor , Wijnen, André J. van , Cool, Simon M. , Ling, Ling , van Wijnen, Andre J

Mayo Clinic

Stem Cells | August 13, 2013 | Volume: 31 | Issue: 12 | Pages: 2724-2736

10.1002/stem.1514 | PMID 23939995 Get It

Abstract Signaling through fibroblast growth factor receptor one (FGFR1) is a known inducer of proliferation in both embryonic and human adult mesenchymal stem cells (hMSCs) and positively regulates maintenance of stem cell viability. Leveraging the mitogenic potential of FGF2/FGFR1 signaling in stem cells for therapeutic applications necessitates a mechanistic understanding of how this receptor stimulates cell cycle progression. Using small interfering RNA (siRNA) depletion, antibody-inhibition, and small molecule inhibition, we establish that FGFR1 activity is rate limiting for self-renewal of hMSCs. We show that FGFR1 promotes stem cell proliferation through multiple mechanisms that unite to antagonize cyclin-dependent kinase (CDK) inhibitors. FGFR1 not only stimulates c-Myc to suppress transcription of the CDK inhibitors p21Waf1 and p27Kip1, thus promoting cell cycle progression but also increases the activity of protein kinase B (AKT) and the level of S-phase kinase-associated protein 2 (Skp2), resulting in the nuclear exclusion and reduction of p21Waf1. The in vivo importance of FGFR1 signaling for the control of proliferation in mesenchymal progenitor populations is underscored by defects in ventral mesoderm formation during development upon inhibition of its signaling. Collectively, these studies demonstrate that FGFR1 signaling mediates the continuation of MSC growth and establishes a receptor target for enhancing the expansion of mesenchymal progenitors while maintaining their multilineage potential. Stem Cells 2013;31:2724–2736
Overdrainage shunt complications in idiopathic normal-pressure hydrocephalus and lumbar puncture opening pressure
Khan, Qurat ul Ain , Wharen, Robert E. , Thomas, Colleen S. , Deen, H. Gordon , Reimer, Ronald, Gerpen, Jay A. van, Graff‐Radford, Neill R. , Grewal, Sanjeet S. , Crook, Julia E.

Mayo Clinic

Journal of Neurosurgery | August 9, 2013 | Volume: 119 | Issue: 6 | Pages: 1498-1502

10.3171/2013.7.jns13484 | PMID 23930853 Get It

Object Management of idiopathic normal-pressure hydrocephalus (iNPH) is hard because the diagnosis is difficult and shunt surgery has high complication rates. An important complication is overdrainage, which often can be treated with adjustable–shunt valve manipulations but also may result in the need for subdural hematoma evacuation. The authors evaluated shunt surgery overdrainage complications in iNPH and their relationship to lumbar puncture opening pressure (LPOP). Methods The authors reviewed the charts of 164 consecutive patients with iNPH who underwent shunt surgery at their institution from 2005 to 2011. They noted age, sex, presenting symptoms, symptom duration, hypertension, body mass index (BMI), imaging findings of atrophy, white matter changes, entrapped sulci, LPOP, valve opening pressure (VOP) setting, number of valve adjustments, serious overdrainage (subdural hematoma requiring surgery), radiological overdrainage (subdural hematomas or hygroma seen on postoperative imaging), clinical overdrainage (sustained or postural headache), other complications, and improvements in gait, urine control, and memory. Results Eight patients (5%) developed subdural hematomas requiring surgery. All had an LPOP of greater than 160 mm H2O and an LPOP-VOP of greater than 40 mm H2O. Radiological overdrainage was more common in those with an LPOP of greater than 160 mm H2O than in those with an LPOP of less than 160 mm H2O (38% vs 21%, respectively; p = 0.024). The BMI was also significantly higher in those with an LPOP of greater than 160 mm H2O (median 30.2 vs 27.0, respectively; p = 0.005). Conclusions Serious overdrainage that caused subdural hematomas and also required surgery after shunting was related to LPOP and LPOP-VOP, which in turn were related to BMI. If this can be replicated, individuals with a high LPOP should have their VOP set close to the LPOP, or even higher. In doing this, perhaps overdrainage complications can be reduced.
Population‐specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO‐PD) consortium
Soto‐Ortolaza, Alexandra I., Aasly, Jan , Abahuni, Nadine, Annesi, Grazia , Bacon, Justin A., Bardien, Soraya , Bozi, Maria , Brice, Alexis , Brighina, Laura , Carr, Jonathan , Chartier‐Harlin, Marie‐Christine , Dardiotis, Efthimios , Dickson, Dennis W. , Diehl, Nancy N. , Ferrarese, Carlo , Fiske, Brian , Gibson, Rachel A. , Hattori, Nobutaka , Ioannidis, John P. A. , Boczarska‐Jedynak, Magdalena , Jasińska‐Myga, Barbara, Jeon, Beom S., Kim, Yun Joong , Klein, Christine , Krüger, Rejko , Kyratzi, Elli, Lesage, Suzanne , Lin, Chin‐Hsien , Lynch, Timothy , Maraganore, Demetrius M. , Mellick, George D. , Mutez, Eugénie , Opala, Grzegorz, Park, Sung Sup , Petrucci, Simona , Puschmann, Andreas , Quattrone, Aldo , Sharma, Manu , Silburn, Peter A., Sohn, Young H. , Tadić, Vera, Theuns, Jessie , Tomiyama, Hiroyuki , Uitti, Ryan J. , Valente, Enza Maria , Broeckhoven, Christine Van , Loo, Simone van de, Vassilatis, Demetrios K. , Vilariño‐Güell, Carles , White, Linda R., Wirdefeldt, Karin , Wu, Ruey‐Meei , Hentati, Fayçal, Farrer, Matthew J. , Ross, Owen A. , Soto‐Beasley, Alexandra I. , Heckman, Michael G. , Elbaz, Alexis , Gibson, Jonathan M. , Hadjigeorgiou, Georgios M. , Nilsson, Christer C. , Stefanis, Leonidas , Wszołek, Zbigniew K. , Dickson, Dennis W , Ross, Owen A , Puschmann, Andreas , Klein, Christine , Bardien, Soraya , Mutez, Eugénie , Valente, Enza Maria , Ioannidis, John P A , Beasley, Alexandra I , Carr, Jonathan , Brice, Alexis , Lin, Chin-Hsien , Wu, Ruey-Meei

Mayo Clinic

Movement Disorders | August 2, 2013 | Volume: 28 | Issue: 12 | Pages: 1740-1744

10.1002/mds.25600 | PMID 23913756 Get It

ABSTRACTBackgroundVariants within the leucine‐rich repeat kinase 2 gene are recognized as the most frequent genetic cause of Parkinson's disease. Leucine‐rich repeat kinase 2 variation related to disease susceptibility displays many features that reflect the nature of complex, late‐onset sporadic disorders like Parkinson's disease.MethodsThe Genetic Epidemiology of Parkinson's Disease Consortium recently performed the largest genetic association study for variants in the leucine‐rich repeat kinase 2 gene across 23 different sites in 15 countries.ResultsHerein, we detail the allele frequencies for the novel risk factors (p.A419V and p.M1646T) and the protective haplotype (p.N551K‐R1398H‐K1423K) nominated in the original publication. Simple population allele frequencies not only can provide insight into the clinical relevance of specific variants but also can help genetically define patient groups.ConclusionsEstablishing individual patient‐based genomic susceptibility profiles that incorporate both risk factors and protective factors will determine future diagnostic and treatment strategies. © 2013 International Parkinson and Movement Disorder Society
Effectiveness of PET/CT in the preoperative evaluation of neck disease
Nguyen, Anthony , Luginbuhl, Adam , Cognetti, David M. , Abel, Katie Van, Bar‐Ad, Voichita , Intenzo, Charles , Keane, William M., Curry, Joseph

Mayo Clinic

The Laryngoscope | July 30, 2013 | Volume: 124 | Issue: 1 | Pages: 159-164

10.1002/lary.24329 | PMID 23901035 Get It

Objectives/HypothesisTo evaluate the utility of positron emission tomography (PET)/computed tomography (CT) for staging the neck in the preoperative setting by comparing it to both CT/magnetic resonance imaging (MRI) and pathologic staging.Study DesignRetrospective review.MethodsSeventy‐one patients with initial diagnosis of head and neck squamous cell carcinoma having preoperative MR or CT imaging and PET/CT with subsequent bilateral neck dissection as part of primary treatment (142 neck dissections). Comparison of cervical nodal metastases based on three separate staging systems: preoperative CT and/or MRI scan, preoperative PET/CT, and pathology.ResultsBoth CT/MRI scans and PET/CT scans statistically predicted pathologic outcomes (P = 0.0001, P = 0.0001, respectively) using Chi square analysis. There was a statistically significant improvement in the prediction of true pathologic disease using PET/CT compared to CT and/or MRI alone (P = 0.005). In a subgroup analysis including only the contralateral neck, this significance persisted (P = 0.013). McNemar's test revealed that subsequent detection of bilateral neck disease by PET/CT scan was significantly superior to MRI or CT alone (P = 0.023).ConclusionIn pathologically positive necks, PET/CT was statistically more reliable at identifying positive disease than CT or MRI alone. Furthermore, such a result is achieved without a statistically significant difference in false positivity between PET/CT and CT or MRI. This suggests that PET/CT positivity, despite negative clinical exam and CT/MRI findings, may be more likely to signify pathologic disease and require appropriate treatment.Level of Evidence4. Laryngoscope, 124:159–164, 2014